Table 1 Clinico-pathological characteristics at primary diagnosis and -652 6N InsDel genotype distribution
From: Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer
| Â | All | CASP8 -652 6N InsDel genotype | P-value | ||
|---|---|---|---|---|---|
InsIns | InsDel | DelDel | |||
n (%) | 200 | 42 (21.0) | 101 (50.5) | 57 (28.5) | Â |
Age at diagnosis (years ± SD) | 56.46 ± 12.1 | 55.00 ± 10.4 | 57.19 ± 12.4 | 56.26 ± 12.6 | 0.676 |
Tumor type | |||||
 Ductal | 136 (68.0) | 28 (20.6) | 68 (50.0) | 40 (29.4) | 0.243 |
 Lobular | 43 (21.5) | 12 (27.9) | 23 (53.5) | 8 (18.6) | |
 Others | 21 (10.5) | 2 (9.5) | 10 (47.6) | 9 (42.9) | |
Tumor size (mm ± SD) | 24.20 ± 16.8 | 23.51 ± 19.2 | 25.11 ± 17.1 | 23.07 ± 14.5 | 0.837 |
Tumor stage | |||||
 pT1 | 107 (53.5) | 24 (22.4) | 53 (49.5) | 30 (28.1) | 0.540 |
 pT2 | 71 (35.3) | 11 (15.5) | 39 (54.9) | 21 (29.6) | |
 pT3+4 | 22 (11.0) | 7 (31.8) | 9 (40.9) | 6 (27.3) | |
Lymph node status | |||||
 pN0 | 115 (57.5) | 24 (20.9) | 61 (53.0) | 30 (26.1) | 0.592 |
 pN+ | 85 (42.5) | 18 (21.2) | 40 (47.1) | 27 (31.8) | |
UICC stage | |||||
 I | 76 (38.0) | 17 (22.4) | 37 (48.7) | 22 (28.9) | 0.442 |
 II | 78 (39.0) | 13 (16.7) | 46 (59.0) | 19 (24.4) | |
 III + IV | 46 (23.0) | 12 (26.0) | 18 (39.1) | 11 (23.9) | |
Grade | |||||
 1 | 71 (37.4) | 16 (22.5) | 35 (49.3) | 20 (28.2) | 0.379 |
 2 | 68 (35.8) | 10 (14.7) | 40 (58.8) | 18 (26.5) | |
 3 | 51 (26.8) | 13 (25.5) | 21 (41.2) | 17 (33.3) | |
Estrogen receptor status | |||||
 negative | 53 (32.5) | 12 (7.4) | 29 (17.8) | 12 (7.4) |  |
 positive | 110 (67.5) | 25 (15.3) | 50 (30.7) | 35 (21.5) | 0.432 |
Her2 status | Â | Â | Â | Â | Â |
 negative | 138 (83.6) | 30 (18.1) | 68 (41.2) | 40 (24.2) | 0.835 |
 positive | 27 (16.4) | 5 (3.0) | 15 (9.1) | 7 (4.2) |  |
Treatment | |||||
 Surgical treatment | |||||
  breast conserving | 50 (25.0) | 10 (20.0) | 23 (46.0) | 17 (34.0) | 0.604 |
  ablative | 150 (75.0) | 32 (21.3) | 78 (52.0) | 40 (26.7) | |
 Adjuvant therapy | |||||
  no adjuvant therapy | 112 (56.0) | 22 (19.6) | 62 (57.1) | 28 (25.0) | 0.285 |
  Tam and/or CMF | 88 (44.0) | 20 (22.7) | 39 (44.3) | 29 (33.0) | |